These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 3537125)

  • 1. Immunolocalization and partial characterization of a nucleolar autoantigen (PM-Scl) associated with polymyositis/scleroderma overlap syndromes.
    Reimer G; Scheer U; Peters JM; Tan EM
    J Immunol; 1986 Dec; 137(12):3802-8. PubMed ID: 3537125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel aspects of autoantibodies to the PM/Scl complex: clinical, genetic and diagnostic insights.
    Mahler M; Raijmakers R
    Autoimmun Rev; 2007 Aug; 6(7):432-7. PubMed ID: 17643929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular characterization of an autoantigen of PM-Scl in the polymyositis/scleroderma overlap syndrome: a unique and complete human cDNA encoding an apparent 75-kD acidic protein of the nucleolar complex.
    Alderuccio F; Chan EK; Tan EM
    J Exp Med; 1991 Apr; 173(4):941-52. PubMed ID: 2007859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The PM-Scl (polymyositis-scleroderma) autoantibody and its nucleolar fluorescence pattern].
    Kühn G; Jarzabek-Chorzelska M; Blaszczyk M; Kolacinska-Strasz Z; Chorzelski TP; Jablonska S
    Dermatol Monatsschr; 1989; 175(8):479-83. PubMed ID: 2676628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C1D is a major autoantibody target in patients with the polymyositis-scleroderma overlap syndrome.
    Schilders G; Egberts WV; Raijmakers R; Pruijn GJ
    Arthritis Rheum; 2007 Jul; 56(7):2449-54. PubMed ID: 17599775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical evaluation of autoantibodies to a novel PM/Scl peptide antigen.
    Mahler M; Raijmakers R; Dähnrich C; Blüthner M; Fritzler MJ
    Arthritis Res Ther; 2005; 7(3):R704-13. PubMed ID: 15899056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibodies to a nuclear/nucleolar antigen in patients with polymyositis overlap syndromes.
    Reichlin M; Maddison PJ; Targoff I; Bunch T; Arnett F; Sharp G; Treadwell E; Tan EM
    J Clin Immunol; 1984 Jan; 4(1):40-4. PubMed ID: 6699138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PM-Scl-75 is the main autoantigen in patients with the polymyositis/scleroderma overlap syndrome.
    Raijmakers R; Renz M; Wiemann C; Egberts WV; Seelig HP; van Venrooij WJ; Pruijn GJ
    Arthritis Rheum; 2004 Feb; 50(2):565-9. PubMed ID: 14872500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of protein components reactive with anti-PM/Scl autoantibodies.
    Gelpi C; Algueró A; Angeles Martinez M; Vidal S; Juarez C; Rodriguez-Sanchez JL
    Clin Exp Immunol; 1990 Jul; 81(1):59-64. PubMed ID: 2199097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antinucleolar antibodies in diagnostics of antiphospholipid syndrome].
    Zabek J; Palacz A; Pyka J; Krzewska I
    Pol Arch Med Wewn; 2008; 118 Suppl():25-30. PubMed ID: 19562966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PM1-Alpha ELISA: the assay of choice for the detection of anti-PM/Scl autoantibodies?
    Mahler M; Fritzler MJ
    Autoimmun Rev; 2009 Mar; 8(5):373-8. PubMed ID: 19103309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-PM/Scl autoantibodies in patients without clinical polymyositis or scleroderma.
    Schnitz W; Taylor-Albert E; Targoff IN; Reichlin M; Scofield RH
    J Rheumatol; 1996 Oct; 23(10):1729-33. PubMed ID: 8895149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Spectrum of antinuclear and anti-cytoplasmic antibodies in dermatomyositis and polymyositis overlap syndromes].
    Meurer M; Hausmann-Martinez-Pardo G; Braun-Falco O
    Hautarzt; 1989 Oct; 40(10):623-9. PubMed ID: 2482267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Scl-86, a marker antigen for diffuse scleroderma.
    van Venrooij WJ; Stapel SO; Houben H; Habets WJ; Kallenberg CG; Penner E; van de Putte LB
    J Clin Invest; 1985 Mar; 75(3):1053-60. PubMed ID: 3980727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autoantibody to RNA polymerase I in scleroderma sera.
    Reimer G; Rose KM; Scheer U; Tan EM
    J Clin Invest; 1987 Jan; 79(1):65-72. PubMed ID: 2432091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum autoantibody to the nucleolar antigen PM-Scl. Clinical and immunogenetic associations.
    Oddis CV; Okano Y; Rudert WA; Trucco M; Duquesnoy RJ; Medsger TA
    Arthritis Rheum; 1992 Oct; 35(10):1211-7. PubMed ID: 1418007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The fibrillarin (Scl-34) autoantibody in systemic scleroderma].
    Kühn G; Jarzabek-Chorzelska M; Blaszczyk M; Chorzelski TP; Jablonska S
    Dermatol Monatsschr; 1990; 176(1):19-26. PubMed ID: 2178987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serological and clinical characterization of anti-dsDNA and anti-PM/Scl double-positive patients.
    Mahler M; Greidinger EL; Szmyrka M; Kromminga A; Fritzler MJ
    Ann N Y Acad Sci; 2007 Aug; 1109():311-21. PubMed ID: 17785320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A highly conserved 72,000 dalton centromeric antigen reactive with autoantibodies from patients with progressive systemic sclerosis.
    McNeilage LJ; Whittingham S; McHugh N; Barnett AJ
    J Immunol; 1986 Oct; 137(8):2541-7. PubMed ID: 3531335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The Scl-70 antibody and its clinical significance].
    Kühn G; Jarzabek-Chorzelska M; Blaszczyk M; Kolacinska-Strasz Z; Chorzelski TP; Jablonska S
    Dermatol Monatsschr; 1989; 175(3):133-47. PubMed ID: 2653887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.